Centessa has been formed as a biotech conglomerate with $250m in funding following a ten-way merger, including multiple spinouts.

US-based pharmaceutical conglomerate Centessa Pharmaceuticals has been formed by investment firm Medicxi and equipped with $250m in series A financing following a large-scale merger that involved a host of spinouts. Three spinouts of University of Cambridge – haemophilia treatment developer Apcintex, pulmonary arterial hypertension therapy developer Morphogen-IX and liver and lung diseases drug producer Z-Factor…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.